KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Share-based Compensation (2016 - 2025)

Neogenomics' Share-based Compensation history spans 16 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 3.43% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $41.3 million, up 155.01%, while the annual FY2025 figure was $41.3 million, 23.65% up from the prior year.
  • Share-based Compensation reached $8.0 million in Q4 2025 per NEO's latest filing, down from $10.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.2 million in Q2 2025 to a low of $100000.0 in Q2 2024.
  • Average Share-based Compensation over 5 years is $6.8 million, with a median of $7.0 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: tumbled 60.69% in 2023, then surged 12114.0% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $10.1 million in 2021, then plummeted by 53.66% to $4.7 million in 2022, then surged by 49.9% to $7.0 million in 2023, then rose by 19.14% to $8.3 million in 2024, then dropped by 3.43% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Share-based Compensation are $8.0 million (Q4 2025), $10.3 million (Q3 2025), and $12.2 million (Q2 2025).